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Abstract
Maintenance of Foxp3 protein expression in regulatory T cells (Treg) is crucial for a balanced immune response. We have
previously demonstrated that Foxp3 protein stability can be regulated through acetylation, however the specific
mechanisms underlying this observation remain unclear. Here we demonstrate that SIRT1 a member of the lysine
deacetylase Sirtuin (SIRT) family, but not the related SIRTs 2–7, co-localize with Foxp3 in the nucleus. Ectopic expression of
SIRT1, but not SIRTs 2–7 results in decreased Foxp3 acetylation, while conversely inhibition of endogenous SIRT activity
increased Foxp3 acetylation. We show that SIRT1 inhibition decreases Foxp3 poly-ubiquitination, thereby increasing Foxp3
protein levels. Co-transfection of SIRT1 with Foxp3 results in increased Foxp3 proteasomal degradation, while SIRT inhibition
increases FOXP3 transcriptional activity in human Treg. Taken together, these data support a central role for SIRT1 in the
regulation of Foxp3 protein levels and thereby in regulation of Treg suppressive capacity. Pharmacological modulation of
SIRT1 activity in Treg may therefore provide a novel therapeutic strategy for controlling immune responses.
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Introduction
Protein acetylation is a tightly controlled process reciprocally
regulated by lysine acetyl transferases (KATs; also known as
histone acetyl transferases) and lysine deacetylases (KDACs; also
known as histone deacetylases). The possibility of manipulating
immune responses through specific modulation of protein
acetylation is being increasingly examined [1]. In vitro and in vivo
studies have demonstrated that treatment with a variety of KDAC
inhibitors increases regulatory T cell (Treg) numbers, Treg
mediated suppression and decreases disease scores in murine
models or arthritis, allograft rejection and colitis [2–5]. Recently,
several studies have reported Foxp3 acetylation, a transcription
factor that is crucial for both Treg development and function [5–
7]. Foxp3 has been reported to associate with the KATs TIP60
and p300 [5;6], while TIP60 and p300 both promote Foxp3
acetylation resulting in both increased Foxp3 protein stability and
chromatin binding [5–7]. The KDACs: HDAC1, HDAC7,
HDAC9 and SIRT1 have all been reported to associate with
Foxp3. However, although they have all been shown to impair
Foxp3 transcriptional activity or decrease protein stability, none of
these KDACs have been reported to directly reduce Foxp3
acetylation [5;6;8]. Very recently it has been shown that Foxp3
protein levels were increased in SIRT1 knock-out Treg resulting in
increased suppressive capacity [9]. However, the molecular
mechanisms underlying these observations or the specificity
between SIRT family members have not yet been evaluated.
In humans, the class III lysine deacetylases also known as
sirtuins (SIRTs) consists of seven members (SIRT1–7). This is a
highly conserved gene family encoding nicotinamide adenine
dinucleotide (NAD)-dependent protein deacetylases. All SIRTs
contain a 250 amino acid core domain that shares 25–60%
sequence identity [10]. Individual SIRTs are localized to specific
subcellular compartments and have been reported to mediate a
variety of cellular processes, including cell differentiation,
chromatin remodelling, DNA repair, endocrine signalling, and
apoptosis [11;12]. Currently little is understood concerning the
role of SIRTs in immune responses, although it has been reported
that SIRT1 deficient mice are more prone to develop autoimmu-
nity and that Treg specific deletion of SIRT1 increases their
immunosuppressive capacity [9;13;14]. The role for specific SIRT
family members in regulating Foxp3 acetylation levels still remains
poorly understood.
Recently, we have reported that acetylation abrogates Foxp3
proteasomal degradation through a reduction in Foxp3 poly-
ubiquitination levels [5]. As both ubiquitination and acetylation
are restricted to lysine residues, a competition model for lysine
modification could be envisaged. Here, we demonstrate that
SIRT1, but not SIRTs 2–7, co-localizes with Foxp3 in the nucleus
and negatively regulates Foxp3 protein levels. SIRT1 deacetylates
Foxp3, resulting in increased Foxp3 poly-ubiquitination and
proteasomal degradation. Finally, we show that SIRT1 inhibition
results in increased FOXP3 transcriptional activity in human
Treg. Taken together, these data suggest that specific modulation
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of SIRT1 activity may provide a therapeutic approach to
pharmacologically control immune responses.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The Study was approved by the
Institutional Review Board of the UMC Utrecht. All participants
provided written informed consent for the collection of samples
and subsequent analysis.
Antibodies, DNA constructs and reagents
The following antibodies were used:mouse anti-Foxp3 clone
PCH101 for FACS analysis (eBioscience, San diego, CA), rabbit
anti-acetyl-lysine (Cell signaling, Danvers, MA), mouse anti-Flag
M2, and mouse anti-tubulin from Sigma (Zwijndrecht, The
Netherlands), Mouse anti-hemaglutinin (HA) clone 12CA5, and
rabbit anti-HSP90 from Santa Cruz Biotechnology (Santa Cruz,
CA), (Sigma), HRP-conjugated anti-ubiquitin Enzo Life Sciences
(Plymouth Meeting, PA, USA). pMT2 HA-Foxp3, pMT2 HA-
Foxp3K22xR, pMT2 Flag-Foxp3 and pRSV-NFATC/A are
previously described [5]. Flag-SIRT1–7 constructs have previously
been described [15] although we had to re-subclone SIRT5.
Cyclohexamide, nicotinamide, and MG132 were purchased from
Sigma.
Cell culture and luciferase assays
HEK293 cells were maintained in DMEM (Invitrogen)
supplemented with 8% heat-inactivated FCS, penicillin and
streptomycin (Invitrogen) at 37uC and 5% CO2. Cells were grown
to 50% confluence in six wells-plates (Nunc, Roskilde, Denmark)
and transfected with a mixture of 1.5 mg DNA and 7.5 ml PEI
overnight, the following day cells were washed twice with PBS and
cultured for 24 hours in medium. Cell lysates were separated by
SDS-PAGE and analyzed by Western blot. For luciferase assay,
cells were transfectied with 1 mg IL–2 promoter luciferase reporter
from Panomics (Fremont, CA) 0.5 mg of pMT2–Foxp3, pcDNA3–
NFATC/A or 0.5 mg pcDNA3 empty vector and 7 mg pMT2
empty vector and 0.05 mg pRLTK renilla, (Promega, Leiden, the
Netherlands) to normalize for transfection efficiency. Cells were
transfected in a six-well plate, two days after transfection the cells
were washed twice with PBS and lysed in 50 ml passive lysis
buffer for 15 minutes, insoluble cell debris was spun down and
the supernatant fraction was assayed for luciferase activity using
Dual-Luciferase Reporter Assay System (Promega, Leiden, The
Netherlands).
Confocal imaging
Localization studies. Transfected HEK293 cells seeded on
poly-L-lysine-coated coverslips were washed with PBS before
fixation using 3% paraformaldehyde (Merck, Nottingham, United
Kingdom) for 10 minutes at 22uC. Cells were pre-incubated with
PBS containing 10% normal donkey serum (Jackson
Immunoresearch) and 0.5% saponin (Sigma-Aldrich) for 15
minutes. Next, cells were incubated for 60 minutes with mouse
anti-Flag-FITC (2.5 mg/ml) and rabbit anti-HA-TRITC 4 mg/ml
(Santa Cruz Biotechnology Inc.) in PBS containing 10% normal
donkey serum and 0.5% saponin. Cells were washed three times
with PBST (0.05% Tween), and mounted in Mowiol 4–88 (Sanofi-
Aventis, Paris, France) containing DAPI. Cells were analyzed with
a 63x objective on a Zeiss LSM 710 fluorescence microscope
(Oberkochen, Germany).
Proximity ligation assay. PLA detection was performed
according to the manufacturer’s protocol (Olink Bioscience,
Uppsala, Sweden). In short, HEK 293 cells grown on coverslips
were fixed using 3% paraformaldehyde for 10 minutes at 22uC.
Subsequently, cells were washed three times with PBS and blocked
for 30 minutes at 22uC in PBS containing 10% normal donkey
serum, 0.5% BSA, and 0.5% saponin. After blocking, cells were
incubated for 60 minutes at 22uC with mouse anti-HA and rabbit
anti-Flag antibodies in PBS containing 10% normal donkey
serum, 0.5% BSA, and 0.5% saponin. Cells were washed three
times with PBST (0.05% Tween) and incubated with the
secondary mouse PLUS and rabbit MINUS antibodies for 1.5
hours at 37uC in the dark. Cells were washed three times in PBST
before detection of the probe using the in situ PLA detection kit
(Abnova, Walnut, USA). Cells were analyzed with a 63x objective
on a Zeiss LSM 710 fluorescence microscope.
Immunoprecipitation and Western blot analysis
HEK 293 cells were lysed in a NP40 lysis buffer (0.05 M Tris-
HCl pH 7.5, 0.5% Nonidet P40, 0.15 M NaCl, 0.01 M EDTA),
immunoprecipitation was performed utilizing anti-flag coupled
beads (Sigma). Beads were washed 3x in lysis buffer, boiled and
samples were separated by SDS-PAGE, electrophoretically
transferred to polyvinylidene difluoride membrane (Millipore,
Bedford, MA), and hybridized with antibodies as indicated.
Immunocomplexes were detected using enhanced chemilumines-
cence (Amersham, Buckinghamshire, United Kingdom).
Generation of iTreg
CD4+CD25- T cells were isolated from human cord blood by
magnetic-activated cell sorting (MACS) and cultured in RPMI
1640 supplemented 10% FCS, 100 units/ml penicillin, 100 mg/ml
streptomycin, and 5610–5 M 2-mercaptoethanol. Foxp3 expres-
sion was induced by culturing the cells for four days in
combination with anti-CD3 anti-CD28 beads dynabeads, 300
IU IL-2 and 10 nM TGF-b.
Quantitative PCR
mRNA was isolated using the trizol according to the
manufacturer’s protocol (Invitrogen), cDNA synthesis was per-
Table 1. Q-PCR primers.
Gene Forward primer Reverse Primer
IL-2 5’-TCCTGTCTTGCATTG-
CACTAAG-39
59-CATCCTGGTGAGTT-
TGGGATTC-39
ITK 59-GTGTTTGCTCCAGA-
TCGTGAG-39
59-GGTTGGATCATATT-
GGGCACAG-39
cMyc 59-TCCGGAAGGACTA-
TCCTGCTG-39
59-GTGTGTTCGCCTCT-
TGACATT-39
ZAP70 59-TGCCCTTCTTCTAC-
GGCAG-39
59-ACGAGCGACAGCA-
CATAGC-39
JAK2 59-CAACAGAGCCTATC-
GGCATGG-39
59-GGGGTTTGATCGTTT-
TCTTTGG-39
SIRT1 59-TGCGGGAATCCAA-
AGGATAA-39
59-CAGGCAAGATGCTG-
TTGCA-39
Foxp3 59-TCAAGCACTGCCA-
GGCG-39
59-CAGGAGCCCTTGT-
CGGAT-39
b2M 5’-CCAGCAGAGAATG-
GAAAGTC-3’
5’-GATGCTGCTTACAT-
GTCTCG-3’
doi:10.1371/journal.pone.0019047.t001
Foxp3 Protein Degradation by Sirtuin-1
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19047
Foxp3 Protein Degradation by Sirtuin-1
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19047
formed using IScript cDNA synthesis kit (Bio-Rad, Hercules, CA).
cDNA samples were amplified using SYBR green supermix (BIO-
Rad), in a MyiQ single-color real time PCR detection system (Bio-
Rad) according to the manufacturer’s protocol. To quantify the
data, the comparative Ct method was used [16]. Relative quantity
was defined as 2-DDCt and b2-microglobulin was used as reference
gene. Primers are listed in Table 1.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney test
(Prism GraphPad Software, San Diego, CA). p,0.05 was
considered statistically significant.
Results
SIRT1 co-localizes with Foxp3 reducing Foxp3 protein
expression levels
Recently, we reported that proteasome-mediated degradation
of Foxp3 is inhibited by p300-mediated acetylation [5].
Increased acetylation prevented poly-ubiquitination and subse-
quently proteasomal degradation in a competition-based man-
ner, as has been described for other transcription factors
including RUNX3, SMAD7, and P53 [17–19]. To further
validate these observations we wished to determine whether
there was specificity among sirtuin (SIRT) lysine deacetylase
Figure 2. Nuclear association of Foxp3 and SIRT1. (A) HEK293 cells were co-transfected with both HA-Foxp3 and Flag-SIRT1, lysed, and Foxp3
was immunoprecipitated and association of proteins was analyzed by Western blotting utilizing anti-Flag antibodies. (B) HA-Foxp3 and Flag-SIRT1
transfected cells were lysed, SIRT1 was immunoprecipitated and the association of Foxp3 was assessed as in (A). (C) SIRT1-Foxp3 interaction in
transfected HEK293 cells was visualized using in situ proximity ligation assay (PLA). Cells were fixed and protein-protein interactions were visualized
utilizing anti-HA and anti-Flag antibodies as described in the Materials and Methods section. Punctate staining (red) indicates Foxp3-SIRT1 interaction
as detected by the assay. Nuclei were stained using Hoechst. Representative images from at least three independent experiments are depicted.
doi:10.1371/journal.pone.0019047.g002
Figure 1. SIRT1 co-localizes with Foxp3 and reduces its expression. (A) HEK293 cells that were transfected with HA-Foxp3 and Flag-tagged
SIRT1-7. Cells were fixed, permiabilized and tagged proteins were visualized using anti-HA (red) or anti-Flag (green) antibodies. DAPI was used to
visualize the nuclei (blue). Figure shows examples of three independent experiments. (B) HEK293 cells were transfected with HA-Foxp3 and Flag-
SIRT1-7. After 48 hours cells were lysed, and Foxp3 levels were analyzed by Western blotting using anti-HA antibodies. Foxp3 protein levels were
quantified and normalized for HSP90 expression. Data show a mean of five independent experiments+ SEM. * P,0.05.
doi:10.1371/journal.pone.0019047.g001
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family members in their capacity to regulate both Foxp3
acteylation and ubiquitination.
Firstly, to analyze potential interactions between SIRT family
members and Foxp3, the subcellular localization of both Foxp3
and SIRTs 1–7 was evaluated. HEK293 cells ectopically
expressing HA-tagged Foxp3 and Flag-tagged SIRTs 1–7 were
fixed and permeabilized. Subsequently, the localization of Foxp3
and SIRTs 1–7 were analyzed utilizing anti-HA and anti-Flag
antibodies. Foxp3 was found specifically localized in the nucleus
and this was unaffected by SIRT co-transfection (Figure 1A).
Although all SIRTs were expressed to similar levels, we could only
detect nuclear localization of SIRT1, 6 and 7. To investigate
specifically which SIRTs could have the capacity to decrease
Foxp3 expression levels, cells were transfected with both HA-
Foxp3 and Flag-SIRTs 1–7, and Foxp3 protein levels were
determined using anti-HA antibodies and blots quantified. Co-
transfection of SIRT1 reproducibly decreased Foxp3 levels, while
SIRTs 2–7 had no observable effect on Foxp3 expression
(Figure 1B). Taken together, these data show that SIRT1
specifically co-localizes with Foxp3 and increased SIRT1 expres-
sion is sufficient to reduce Foxp3 protein levels.
SIRT1 directly associates with Foxp3
To determine whether SIRT1 associates with Foxp3 a co-
immunoprecipitation assay was performed. HEK293 cells were
transfected with both HA-Foxp3 and Flag-SIRT1, lysates were
prepared and Foxp3 or SIRT1 were immunoprecipitated. SIRT1
was detected when Foxp3 was immunoprecipitated and vice versa,
demonstrating their association (Figure 2A, B). To further verify
these results an in situ proximity ligation assay (PLA) was
performed (see Materials and Methods). Since a PLA signal can
only be obtained when the proteins of interest are in extreme close
proximity, this technique enables the detection of direct protein-
protein interactions in cells. Association of transfected Foxp3 and
SIRT1 in HEK293 cells was observed and the interaction was
localized specifically in the nucleus (Figure 2C; middle panel). The
specificity of this interaction was confirmed since association of
Foxp3 with SIRT3 was not observed by PLA (Figure 2C; right
panel).
SIRT1-mediated deacetylation increases Foxp3 poly-
ubiquitination
To further evaluate the molecular mechanism underlying the
effect of SIRT1 on Foxp3 protein levels, we first determined
whether SIRT1 could decrease Foxp3 acetylation levels. HEK293
cells were co-transfected with HA-Foxp3 and Flag-SIRT1, lysates
were prepared and HA-Foxp3 was immunoprecipitated, and
acetylation was visualized by Western blotting using an anti-acetyl
lysine antibody. Levels of Foxp3 acetylation were considerably
reduced by SIRT1 co-transfection (Figure 3A). To further validate
these data we utilized nicotinamide (NAM), the widely used
Sirtuin inhibitor [20;21]. NAM treatment increased acetylation of
Figure 3. SIRT1-mediated deacetylation increases Foxp3 poly-ubiquitination. (A) HEK293 cells ectopically expressing HA-Foxp3 were
transfected with Flag-SIRT1. Cell lysates were prepared and HA-Foxp3 was immunoprecipitated. Acetylated Foxp3 was visualized by Western blotting
using anti-acetylated lysine antibodies. (B) Analysis of Foxp3 acetylation after treatment with 20 mM nicotinamide (NAM) for 16 hours as in (A).
(C) Cells were transfected with Flag-Foxp3 and treated with 20 mM NAM (for three hours), Foxp3 was immunoprecipitated from cell lysates and
ubiquitination was analyzed by Western blotting utilizing anti-ubiquitin antibodies. * Indicates aspecific band. Data shown are representative of three
independent experiments.
doi:10.1371/journal.pone.0019047.g003
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Foxp3 (Figure 3B), demonstrating that SIRTs can indeed
modulate Foxp3 deacetylation. Since we previously demonstrated
that acetylation of Foxp3 results in increased protein levels by
preventing poly-ubiquitination [5], the effect of SIRT inhibition
on Foxp3 ubiquitination was also analyzed. Cells ectopically
expressing HA-Foxp3 were treated for three hours with the
proteasome inhibitor MG132, lysed and Foxp3 was immunopre-
cipitated. Ubiquitinated Foxp3 was visualized by Western blotting
utilizing anti-ubiquitin antibodies. SIRT inhibition dramatically
reduced Foxp3 poly-ubiquitination (Figure 3C). Taken together,
these data show that SIRT1-mediated deacetylation results in
increased Foxp3 poly-ubiquitination.
SIRT1 regulates Foxp3 proteasomal degradation
Since we observed that SIRT1 can decrease Foxp3 deacetyla-
tion, thereby increasing its poly-ubiquitination, the effect of SIRT1
on Foxp3 protein stability was further investigated. HEK293 cells
were co-transfected with HA-Foxp3 and Flag-SIRT1 and treated
with the proteasome inhibitor MG132. After lysis, Foxp3 protein
levels were analyzed by Western blotting utilizing anti-HA
antibodies. Co-transfection of SIRT1 decreased Foxp3 protein
levels, and this was reversed by MG132 treatment (Figure 4A).
These data show that the SIRT1-mediated decrease in Foxp3
expression levels is proteasome-dependent. To further validate
these observations, cells were transfected with HA-Foxp3 and
treated with NAM for 16 hours. SIRT inhibition resulted in
increased Foxp3 levels as expected (Figure 4B), while MG132
treatment had no additional effect on Foxp3 protein levels. To
confirm that SIRT inhibition regulates Foxp3 expression post-
translationally, cells were treated with cyclohexamide (CHX), an
inhibitor of translation. CHX treatment of cells ectopically
expressing HA-Foxp3 resulted in reduced Foxp3 protein levels
(Figure 4C). However, there was no effect of CHX-treatment on
Foxp3 protein levels when the cells were also treated with NAM,
confirming that SIRT1 inhibition increases Foxp3 protein
stability.
To confirm that deacetylation of Foxp3 is directly responsible
for reduced proteasomal degradation we generated a Foxp3
mutant in which all lysines had been mutated (HA-Foxp3 K22xR),
thereby preventing both acetylation and ubiquitination of Foxp3.
Cells were transfected with wild-type Foxp3 or Foxp3 K22xR and
subsequently treated with NAM. Foxp3 K22xR protein levels
were increased compared to wild-type presumably since the Foxp3
K22xR mutant can no longer be poly-ubiquitinated (Figure 4D).
Treatment with NAM again resulted in increased protein levels of
wild-type Foxp3, however Foxp3 K22xR expression levels
remained unaffected by SIRT inhibition.
To determine whether SIRTs can also regulate Foxp3 protein
expression in human CD4+ Treg, CD4+ cells from human PBMC
were cultured in the presence of IL-2, anti-CD3 and anti-CD28 to
generate iTreg as previously described [5]. iTreg were treated with
NAM and the percentage of CD4+Foxp3+ T cells, as well as
Foxp3 protein levels per cell were determined by FACS. NAM
treatment resulted in both increased CD4+Foxp3+ cell numbers as
well as increased Foxp3 protein levels per cell (Figure 4E, F).
Taken together, these data show that SIRT-mediated deacetyla-
tion increases proteasome mediated Foxp3 degradation in Treg.
SIRT1 activity inhibits Foxp3 transcriptional output
To determine whether SIRT1-mediated Foxp3 deacetylation
also results in impaired Foxp3 transcriptional output an IL-2
promoter reporter assay was performed. HEK293 cells were
transfected with IL-2 promoter luciferase, NFAT, Foxp3 and
SIRT1 as previously described [5]. Transfection of Foxp3 resulted
in suppression of IL-2 promoter activity (Figure 5A). Co-transfection
with SIRT1 significantly impaired Foxp3mediated repression of the
IL-2 promoter. To control for a direct effect of SIRT1 on the IL-2
promoter reporter, luciferase activity was analyzed utilizing the
Foxp3 K22xR acetylation-deficient mutant. Foxp3 K22xR was
unable to inhibit reporter activity, and this was unaffected by SIRT1
co-transfection. These data further validates the observation that
Foxp3 deacetylation results in reduced Foxp3-mediated transcrip-
tional repression. Since we have established that SIRT1 decreased
Foxp3 protein levels through proteasomal degradation Foxp3,
SIRT1 mRNA expression levels were analyzed during Treg
induction. Treg were induced by stimulating CD4+CD25- cells
from cord blood peripheral blood mononuclear cells (PBMC) using
anti-CD3 anti-CD28 coupled dynabeads in combination with IL-2
and TGF-b for five days. Cells were isolated at day 0, 3, and 5, and
SIRT1 and Foxp3 mRNA expression were analyzed by qRT-PCR
(Figure 5B). Foxp3 mRNA levels were dramatically upregulated
during iTreg differentiation, as expected. Furthermore, a significant
decrease of SIRT1 mRNA at both day three and five was observed.
We next analyzed whether increased Foxp3 protein levels by SIRT
inhibition also results in increased Foxp3 transcriptional activity.
Human CD4+ cells were isolated from PBMC and differentiated
towards Foxp3+ iTreg in the presence or absence of NAM. mRNA
expression of multiple Foxp3 transcriptional targets (IL-2, ITK,
Zap70, c-Myc, Jak2) were analyzed [22]. Treatment with NAM
reduced mRNA levels of all Foxp3 transcriptional targets in a dose-
dependent manner (Figure 5C). Taken together, these data suggest
that increased Foxp3 protein levels by SIRT1 inhibition also results
in increased suppression of multiple Foxp3 transcriptional targets in
iTreg.
Discussion
Stable expression of the transcription factor Foxp3 is essential
for the development and function of Treg [23–26]. Although TCR
activated T cells can transiently express Foxp3 protein, these cells
lack suppressive capacities [27;28]. While many studies have
focused on the regulation of Foxp3 promoter activity, proteasome
mediated regulation of Foxp3 expression levels has not yet been
extensively investigated. Recently, we established that Foxp3
acetylation increases protein levels, and that deacetylation by
KDACs decreases Foxp3 protein expression through increased
proteasomal degradation [5]. Here we demonstrate that SIRT1,
but not SIRTs 2–7, co-localizes with Foxp3 in the nucleus. SIRT1
Figure 4. SIRT1 regulates Foxp3 degradation. (A) HEK293 cells were co-transfected with HA-Foxp3 and Flag-SIRT1 and treated with 2 mM
MG132 for 16 hours. Cells were lysed and Foxp3 protein levels were visualized by Western blotting using anti-HA antibodies. (B) Cells were
transfected with HA-Foxp3 and treated with 20 mM NAM for 16 hours, Foxp3 protein levels were analyzed by Western blotting using anti-HA
antibodies. (C) Cells ectopically expressing HA-Foxp3 were treated with both 20 mM NAM and 5 mg/ml cyclohexamide (CHX) for 16 hrs and Foxp3
levels were analyzed by Western botting. (D) HA-Foxp3 or a HA-tagged Foxp3 mutant in which all lysines were mutated to argenines (HA-Foxp3
K22xR) was transfected into HEK293 cells. Cells were treated with 20 mM NAM for 16 hours. Cell lysates were prepared and Foxp3 levels were
evaluated by immunoblotting for HA and HSP90 as control. (E) CD4+ T cells isolated from human PBMC were cultured in the presence of 300 IU/ml IL-
2, 2.0 mg/ml anti-CD28, and 1.5 mg/ml plate-bound anti-CD3 and treated NAM (1 or 9 mM). After 4 days, the percentage of Foxp3+CD25+ cells was
analyzed by FACS. (F) Histogram of the data shown in (E). Data are representative of at least three independent experiments.
doi:10.1371/journal.pone.0019047.g004
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Figure 5. SIRT1 inhibition increases Foxp3 transcriptional output. (A) Utilizing an IL-2 promoter reporter, Foxp3 transcriptional function was
analyzed. HEK293 cells were transfected with an IL-2 promoter luciferase reporter, NFAT, Foxp3, Foxp3 K22xR and SIRT1, cells were lysed and assayed
as described in the Materials and Methods. Luciferase values were normalized for co-transfected renilla to correct for transfection efficiency. (B) iTregs
were generated by culturing human CD4+CD25- human T cells with anti-CD3 and anti-CD28 coupled beads, in combination with 10 ng/ml TGF-b and
300 U/ml IL-2 for 5 days. At day 0, 3, 5 cells were harvested and mRNA expression of SIRT1 and Foxp3 was analyzed by qRT-PCR. (C) Freshly isolated
human CD4+ T cells were cultured in the presence of 300 U/ml IL-2, anti-CD3 and anti-CD28 and 0, 1 or 9 mM NAM for three days. mRNA expression
of multiple transcriptional targets of Foxp3 was analyzed by qRT-PCR. Data are representative of at least three independent experiments, * P,0.05,
** P,0.01.
doi:10.1371/journal.pone.0019047.g005
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can specifically regulate Foxp3 deacetylation, resulting in
increased Foxp3 poly-ubiquitination and reduced Foxp3 protein
levels. In addition, we show that SIRT inhibition results in both
increased Foxp3 protein levels and transcriptional output in
human iTreg. Taken together, these data provide novel insights
into regulatory mechanisms modulating Foxp3 protein expression
and thereby Treg numbers and suppressive capacity.
Several classes of KDAC inhibitors are currently being used as
anti-inflammatory agents [1]. We and others have recently
reported that inhibition of KDAC activity utilizing broad-
spectrum KDAC inhibitors, including TSA, SAHA, Tubacin,
BML-210, MS-275, SB, and Bufexmac can increase Treg-
mediated suppression in in vitro suppression assays [4;5;29].
Treatment with TSA, SAHA, and VPA have also been shown
to reduce colitis, and increase cardiac and island allograft survival
in vivo in mouse models [2–4]. Importantly, Beier et al. recently
reported that in both murine sirt1 knock-out Treg, and Treg in
which SIRT1 was specifically inhibited utilizing SIRT1 inhibitor
EX-527, Treg mediated suppression was increased, resulting in
increased cardiac allograft survival [9]. However, the specificity if
SIRT family members for Foxp3 and the molecular mechanisms
underlying these observations were not evaluated. Our data
support the observations of Beier, et al. and provide a molecular
mechanism for the increased Treg mediated suppression in vivo. In
contrast, it was reported that mice with a global deletion of sirt1
are more prone to develop autoimmunity [13;14]. Removing
SIRT1 in all cell types may account for the difference in
phenotype, since here SIRT1 could potentially also modulate
processes of DC mediated antigen presentation, T cell maturation
or effector T cell activity.
Here we demonstrate that treatment of human CD4+ T cells
with SIRT inhibitor nicotinamide increases the number of
CD4+Foxp3+ Treg as well as the amount of Foxp3 per cell by
impaired Foxp3 degradation, increasing Treg suppressive capac-
ity. Nicotinamide, also known as vitamin B3, is a water-soluble
vitamin and its use in the treatment of auto-immunity would
therefore be cheaper and relatively safe compared to other
commercially available KDAC inhibitors. In several human trials
nicotinamide treatment has already shown to significantly reduce
the development of type 1 diabetes [30;31]. In addition,
nicotinamide treatment of patients with arthritis has been observed
to result in disease remission [32;33]. IPEX patients have an
enhanced susceptibility for diabetes type 1 and Treg adoptive
transfer impairs diabetes in NOD mice [34], while depletion of
Treg in collagen-induced arthritis mice hastens the onset of disease
[35]. With this in mind, it is interesting to speculate that the
positive effect of nicotinamide observed in current patient trials
could be Treg mediated [36;37].
As previously mentioned, activated T cells can also transiently
upregulate Foxp3 expression levels [27]. CD4 positive T cells
stimulated with phorbol 12-myristate 13-acetate (PMA) and Ca2+
ionophore, or anti-CD3 and anti-CD28, transiently express both
Foxp3 mRNA and protein [27;38;39]. In general, these Foxp3
positive cells do not develop a Treg phenotype and are unable to
suppress proliferation or cytokine production of co-cultured T cells
[27;38]. However, a small percentage of stimulated T cells express
high and stable levels of Foxp3 and have also been demonstrated
to be immune suppressive [27;28]. Murine Treg in which Foxp3 is
conditionally deleted, lose their suppressive phenotype resulting in
the production of Th1 cytokines[26]. These observations under-
score the prevailing dogma that stable, high expression of Foxp3 is
essential for maintaining the Treg phenotype, and stabilization of
Foxp3 expression levels is a critical step for the development of
induced Treg. It has recently been shown that SIRT1 is
significantly upregulated in activated T effector cells, while in
Treg SIRT1 is downregulated upon activation [9]. Since we show
that SIRT1 mediated deacetylation of Foxp3 results in impaired
protein stability, we propose a model in which Foxp3 acetylation
may provide a post-translational ‘‘switch’’ allowing the develop-
ment of iTreg. In this model, T cell activation results in expression
of Foxp3 which will be stable and high when Foxp3 is acetylated,
resulting in the development of suppressive iTreg. However, in the
presence of active SIRT1, as reported in activated T effector cells
[9], T cells will not develop a Treg phenotype since Foxp3 will be
deacetylated, subsequently poly-ubiquitinated and degraded by
the proteasome. Therefore control of SIRT1 activity may be a
defining factor for the initiation of a Foxp3-dependent transcrip-
tional program and the development of Treg.
Taken together, we have demonstrated that SIRT1 but not
SIRTs 2–7 directly deacetylates Foxp3, resulting in increased
Foxp3 poly-ubiquitination and proteasomal degradation, thereby
abrogating Treg functionality. Our findings suggest that manip-
ulation of SIRT1 levels or activity may provide a novel therapeutic
strategy to control (inappropriate) immune responses.
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